Abstract
Background: Interferon-β is an attractive drug for repurposing and use in the treatment of COVID-19, based on its in vitro antiviral activity and the encouraging results from clinical trials. The aim of this study was to analyze the impact of early interferon-β treatment in patients admitted with COVID-19 during the first wave of the pandemic.
Methods: This post hoc analysis of a COVID-19@Spain multicenter cohort included 3808 consecutive adult patients hospitalized with COVID-19 from 1 January to 17 March 2020. The primary endpoint was 30-day all-cause mortality, and the main exposure of interest was subcutaneous administration of interferon-β, defined as early if started ≤ 3 days from admission. Multivariate logistic and Cox regression analyses were conducted to identify the associations of different variables with receiving early interferon-β therapy and to assess its impact on 30-day mortality. A propensity score was calculated and used to both control for confounders and perform a matched cohort analysis.
Results: Overall, 683 patients (17.9%) received early interferon-β therapy. These patients were more severely ill. Adjusted HR for mortality with early interferon-β was 1.03 (95% CI, 0.82-1.30) in the overall cohort, 0.96 (0.82-1.13) in the PS-matched subcohort, and 0.89 (0.60-1.32) when interferon-β treatment was analyzed as a time-dependent variable.
Conclusions: In this multicenter cohort of admitted COVID-19 patients, receiving early interferon-β therapy after hospital admission did not show an association with lower mortality. Whether interferon-β might be useful in the earlier stages of the disease or specific subgroups of patients requires further research.
Keywords: COVID-19; Interferon-β; Mortality; SARS-CoV-2; Treatment.
【저자키워드】 COVID-19, Treatment, SARS-CoV-2, Mortality, Interferon-β, 【초록키워드】 Treatment, pandemic, therapy, interferon, clinical trials, in vitro, antiviral activity, Cohort, Research, Patient, Hospital admission, multicenter, First wave, Admission, COVID-19 patients, association, 30-Day mortality, Propensity score, administration, primary endpoint, Analysis, Cox regression, subcutaneous administration, Logistic, 95% CI, all-cause mortality, multivariate, Stage, confounders, lower mortality, cohort analysis, variable, confounder, defined, analyzed, identify, the disease, conducted, receiving, calculated, patients hospitalized, subgroups of patient, with COVID-19, 【제목키워드】 Treatment, Cohort, Impact, multicenter, Analysis, prognosis of patient, with COVID-19,